Squarepoint’s Celularity CELU Stock Holding History

Squarepoint’s Portfolio CELU Stock Details CELU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,022	Closed	-$13.2K	–	3282
2022 Q4	$13.2K	Buy	+1,022	New	+$18.8K	﹤0.01%	3117

Other funds holding CELU

SIC

Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return

CVSC

C.V. Starr & Co New York $192M AUM 35.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BFO

Biltmore Family Office Charlotte, North Carolina $716M AUM 21.09% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Squarepoint's CELU Position: Q1 2023 in Review

Squarepoint sold out of Celularity (CELU) in Q1 2023, closing a stake of 1,022 shares — an estimated $13.2K sold.

Squarepoint first reported a position in CELU in Q4 2022 and held it in 1 quarter. The position peaked at $13.2K in Q4 2022. 61 funds tracked by Wall St. Rank hold CELU as of Q1 2023.

Squarepoint reported no remaining Celularity position as of Q1 2023 after selling out during the quarter.
Squarepoint sold 1,022 Celularity shares in Q1 2023, an estimated $13.2K.
Squarepoint first reported a position in Celularity in Q4 2022 and held it in 1 quarter.
Squarepoint's Celularity position peaked at $13.2K in Q4 2022.
61 funds tracked by Wall St. Rank held Celularity as of Q1 2023.

Based on Squarepoint's 13F filing for Q1 2023, filed 15 May 2023.